Tyroserleutide hydrochloride 可从猪脾脏的降解产物中分离得到，是一种小分子三肽，在体内外均可抑制肿瘤生长。
货号:ajcx15692
CAS:852982-42-4
分子式:C18H28ClN3O6
分子量：417.88
溶解度:DMSO: 250 mg/mL (598.26 mM)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

Tyroserleutide hydrochloride, isolated from the degradation products of porcine spleen[1], is a small molecular tripeptide which inhibits tumor growth both in vitro and in vivo[2].

Tyroserleutide (YSL) exhibits immuno-modulating effects, such as enhancing concanavalin (ConA) induced proliferation of mouse spleen lymphocytes, phagocytosis of mouse peritoneal macrophages, and the activity of natural killer (NK) cells[1].Tyroserleutide (YSL), an immunologically therapeutic tripeptide, can promote hepatocarcinoma cell (H22) apoptosis through downregulating Bcl-2 and cyclin D1 expression[2]. Tyroserleutide is an ideal choice for inducing apoptosis of liver tumor cells[2]. Tyroserleutide inhibits tumor growth and does not cause severe toxicities in the major organs. Tyroserleutide can inhibit tumor cell migration[2].

Tyroserleutide (10-80 μg/kg; injection (i.p.) one time every day until mice are dead) displays obvious anti-tumor activity. Tyroserleutide significantly prolongs the survival time of the murine H22 implanted mice[1]. Animal Model: Female Kun-Ming mice (18-22 g, 6 week old) with H22 tumor model[1]

[1]. Wang C, et al. Studies on the large scale synthesis and anti-tumor activity of YSL. Prep Biochem Biotechnol. 2003 Aug;33(3):189-95. [2]. Liang P, et al. pH-Triggered Conformational Change of Antp-Based Drug Delivery Platform for Tumor Treatment with Combined Photothermal Therapy and Chemotherapy. Adv Healthc Mater. 2019 Aug;8(15):e1900306.